Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07165015 · ClinicalTrials.gov registry record · Phase 1
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
A Phase 1 study of Healthy and Renal Impairment, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 4
- Study locations
NCT07165015 is a Phase 1 study of Healthy and Renal Impairment that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 32 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT07165015, a Phase 1 study of Healthy and Renal Impairment, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to assess the amount of LY3537031 that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants.
Conditions Studied
Interventions
- DRUG LY3537031
Study Locations (4)
Florida
- Omega Research Orlando LLC - Orlando
- Orlando Clinical Research Center - Orlando
Indiana
- Indiana University School of Medicine - Indianapolis
Other
- New Zealand Clinical Research Christchurch - Christchurch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-09-18 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07165015
The ClinicalTrials.gov registry entry for NCT07165015 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which LY3537031 is the first listed.
NCT07165015 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Florida, Indiana, Other.
Frequently Asked Questions
What is clinical trial NCT07165015 about?
NCT07165015 is a clinical study titled "A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment". The purpose of this study is to assess the amount of LY3537031 that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants.
What is the current status of trial NCT07165015?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-09-18. Estimated completion is 2026-03.
What conditions does trial NCT07165015 study?
This clinical trial studies the following conditions: Healthy, Renal Impairment, Renal Insufficiency, End Stage Renal Disease (ESRD).
What interventions are being tested in trial NCT07165015?
The interventions under investigation include: LY3537031 (DRUG).
Who is sponsoring clinical trial NCT07165015?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07165015 being conducted?
This trial has 4 study locations across Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.